

पेटेंट कार्यालय
शासकीय जर्नल

**OFFICIAL JOURNAL
OF
THE PATENT OFFICE**

निर्गमन सं. 12/2026
ISSUE NO. 12/2026

शुक्रवार
FRIDAY

दिनांक: 20/03/2026
DATE: 20/03/2026

पेटेंट कार्यालय का एक प्रकाशन
PUBLICATION OF THE PATENT OFFICE

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202611011206 A

(19) INDIA

(22) Date of filing of Application :03/02/2026

(43) Publication Date : 20/03/2026

(54) Title of the invention : SYNTHESIS AND ANTI-INFLAMMATORY EVALUATION OF N-(2-NITRO)BENZYLIDENE ANTHRANILIC ACID

(51) International classification	:A61P 29/00, A61K 31/196, A61K 31/195, A61K 31/44, C07C 229/60	(71)Name of Applicant : 1)Shweta Verma Address of Applicant :Pharmacy Academy, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh Uttar Pradesh India 2)Uma Agarwal 3)Saroj Verma (72)Name of Inventor : 1)Shweta Verma 2)Uma Agarwal 3)Saroj Verma
(31) Priority Document No	:NA	
(32) Priority Date	:NA	
(33) Name of priority country	:NA	
(86) International Application No	:	
Filing Date	:01/01/1900	
(87) International Publication No	: NA	
(61) Patent of Addition to Application Number	:NA	
Filing Date	:NA	
(62) Divisional to Application Number	:NA	
Filing Date	:NA	

(57) Abstract :

The present invention relates to the synthesis and pharmacological evaluation of a novel anthranilic acid derivative, N-(2-nitro) benzylidene anthranilic acid, developed for the treatment of inflammatory conditions. The compound was synthesized using a simple and reproducible method and characterized by thin layer chromatography, infrared spectroscopy, and ¹H-NMR spectroscopy to confirm its structure and purity. Pharmacological assessment was carried out using the carrageenan-induced rat paw edema model, where the compound demonstrated significant anti-inflammatory activity when compared with a standard drug. The results indicate that the synthesized compound exhibits promising therapeutic potential with effective inhibition of inflammation. This invention provides a novel anthranilic acid-based molecule that may serve as a lead compound for further pharmaceutical development and safer anti-inflammatory therapy.

No. of Pages : 14 No. of Claims : 2